The Interface between Rheumatology and Dermatology

Why Rheumaderm?
  • Carmel MalliaEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)


Although the division of medicine into specialties according to different systems is convenient, it is also artificial: the different systems interact and many diseases overlap both in their pathological features as well as their clinical expression. Many examples of such interactions are seen in the connective tissue disorders, where rheumatological and dermatological manifestations may be prominent features. In some of them the skin rash may be a diagnostic marker (e.g., systemic lupus erythematosus, dermatomyositis). Joint involvement can also be found in “primary” skin disorders such as psoriasis; certain infections can produce both skin and joint manifestations including a number of fairly common viral disorders as well as Lyme borelliosis and the acquired immune deficiency syndrome (A.I.D.S.) The skin may also be the major target of toxicity from a number of drugs, particularly those that are used in the management of rheumatic disorders.


Systemic Lupus Erythematosus Infective Endocarditis Familial Mediterranean Fever Skin Rash Connective Tissue Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yung RL, Richardson BC. Drug Induced Lupus. Rheum Dis Clin North Am. 20: 61–86. 1994.PubMedGoogle Scholar
  2. 2.
    Price EJ, Venables PJ. Drug-induced lupus. Drug Saf. 12: 283–290. 1995PubMedCrossRefGoogle Scholar
  3. 3.
    Gunnarson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S, Ringertz B. Predisposing factors in sul-phasalazine-induced systemic lupus erythematosus. Br J Rheumatol. 36: 1089–1094. 1997.CrossRefGoogle Scholar
  4. 4.
    McGuiness M, Frye RA, Deng JS. Atenolol-induced lupus erythematosus. J Am Acad Dermatol. 37: 298–299. 1997.PubMedCrossRefGoogle Scholar
  5. 5.
    Eyanson S, Greist MC, Brandt KD, Skinner B. Systemic lupus erythematosus: association with psoralen-ultraviolet A treatment of psoriasis. Arch Dermatol 115: 54–56. 1979.PubMedCrossRefGoogle Scholar
  6. 6.
    McGrath H Jr., Scopelitis E, Nesbitt LT Jr. Subacute cutaneous lupus erythematosus during psoralen ultraviolet A therapy. Arthrit Rheum 33: 302–303. 1990.CrossRefGoogle Scholar
  7. 7.
    Kilbourne EM, Philen RM, Kamb ML, Falk H. Tryptophan produced by Showa Denko and epidemic eosi-nophilia-myalgia syndrome. J Rheumatol (Suppl). 46: 81–88. 1996.Google Scholar
  8. 8.
    Bigby M, Stern R. Cutaneous reactions to nonsteroidal anti-inflammatory drugs. A review. J Am Acad Dermatol. 12: 866–876. 1985.CrossRefGoogle Scholar
  9. 9.
    Schopf E, Stuhmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 127: 839–842. 1991.Google Scholar
  10. 10.
    Wilkinson SM, Smith AG, Davis MJ, Mattey DL, Dawes PT. Suspected drug toxicity in rheumatoid arthritis — an evaluation. Br J Rheumatol 32: 798–803 (1993)PubMedCrossRefGoogle Scholar
  11. 11.
    Roth DE, Spencer LV, Abrens EM. Cutaneous reactions to drugs used for rheumatologic disorders. Med Clin North Am. 73: 1275–1298. 1989.PubMedGoogle Scholar
  12. 12.
    Broggini M, Baratelli E, Cappelli A, Crespi E, Filardi PG, Volonte S. Cutaneous side effects induced by D-penicillamine in the treatment of rheumatoid arthritis. Minerva Med 81: 197–201 1990.PubMedGoogle Scholar
  13. 13.
    Skeith KJ, Russell AS. Adverse reactions to sulfasalazine. J Rheumatol 15: 529–530. 1988.PubMedGoogle Scholar
  14. 14.
    Pullar T. Adverse effects of sulphasalazine. Adverse Drug React Toxicol Rev. 11: 93–l09. 1992.PubMedGoogle Scholar
  15. 15.
    Koranda FC. Antimalarials. J Am Acad Dermatol. 4: 650–655. 1981.PubMedCrossRefGoogle Scholar
  16. 16.
    Levy H. Chloroquine-induced pigmentation. Case reports. S. Afr Med J. 62: 735–737. 1982.Google Scholar
  17. 17.
    Veraldi S, Schianchi-Veraldi R, Scarabelli G. Pigmentation of the gums following hydroxycholoroquine therapy. Cutis. 49: 281–281. 1992.PubMedGoogle Scholar
  18. 18.
    Abel EA. Diagnosis of drug-induced psoriasis. Semin Dermatol. 11: 269–274. 1992.PubMedGoogle Scholar
  19. 19.
    Segal R, Caspi D, Tishler M, Fishel B, Yaron M. Accelerated nodulosis and vasculitis during methotrexate therapy for rheumatoid arthritis. Arthritis Rheum. 31: 1182–1185. 1988.PubMedCrossRefGoogle Scholar
  20. 20.
    Combe B, Didry C, Gutierrez M, Anaya JM, Sany J. Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis. Eur J Med. 2: 153–156. 1993.PubMedGoogle Scholar
  21. 21.
    Wilson DJ, Kay V, Charig M, Hughes DG, Creasy Ts. Skeletal hyperostosis and extraosseous calcification in patients receiving long-term etretinate (Tigason). Br J Dermatol 119: 597–607. 1988.PubMedCrossRefGoogle Scholar
  22. 22.
    Van Dooren-Greebe RJ, Lemmens JA, De Boo T, Hangs NM, Kuljpers AL, Van de Kerkhof. Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol 134: 71–76. 1996.PubMedCrossRefGoogle Scholar
  23. 23.
    Campbell RR, Hawkins SJ, Maddison PJ. Reckless JP. Limited joint mobility in diabetes mellitus. Ann Rheum Dis. 44: 93–97. 1985.PubMedCrossRefGoogle Scholar
  24. 24.
    Brik R, Berant M, Vardi P. The scleroderma-like syndrome of insulin-dependent diabetes mellitus. Diabetes Metab Rev. 7: 120–128. 1991.PubMedCrossRefGoogle Scholar
  25. 25.
    Sculte L, Roberts MS, Zimmerman C, Ketler J, Simon LS. A quantitative assessment of limited joint mobility in patients with diabetes. Arthritis Rheum. 36: 1429–1443. 1993.CrossRefGoogle Scholar
  26. 26.
    Rosenbloom AL, Silverstein JH. Connective tissue and joint disease in diabetes mellitus. Endocrinol Metab Clin North Am. 25: 473–83. 1996.PubMedCrossRefGoogle Scholar
  27. 27.
    Azizi E, Fisher BK. Cutaneous manifestations of familial Mediterranean fever. Arch Dermato. 112: 364–366. 1976.CrossRefGoogle Scholar
  28. 28.
    Majeed HA, Quabazard Z, Hijazi Z, Farwana S, Harshani F. The cutaneous manifestations in children with familial Mediterranean fever (recurrent hereditary polyserositis). A six-year study. QJ Med. 278: 607–616. 1990.Google Scholar
  29. 29.
    Daoud MS, Gibson LE, Daoud S, el-Azhary RA. Chronic hepatitis C and skin diseases: a review. Mayo Clin Proc. 70: 559–564. 1995.PubMedCrossRefGoogle Scholar
  30. 30.
    Duffy J. Lyme Disease: a clinical review. Minn Med. 74: 21–26. 1991.PubMedGoogle Scholar
  31. 31.
    Burgorfer W. Lyme borreliosis: ten years after discovery of the etiologic agent, Borrelia burgdorferi. Infection. 19: 257–262. 1991.CrossRefGoogle Scholar
  32. 32.
    Calabrese LH. Human immunodeficiency virus (HIV) infection and arthritis. Rheum Dis Clin North Am. 19: 477–488. 1993.PubMedGoogle Scholar
  33. 33.
    Uthayamumar S, Nandwani R, Drinkwater T, Nayagam AT, Darley CR. The prevalence of skin disease in HIV infection and its relationship to the degree of immunosuppression. Br J Dermatol. 137: 595–598. 1997.CrossRefGoogle Scholar
  34. 34.
    Hughes GR, Khamashta MA. The Antiphospholipid Syndrome. J R Coll Physicians Lond. 28: 301–314. 1994.PubMedGoogle Scholar
  35. 35.
    Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol. 36: 970–982. 1997.PubMedCrossRefGoogle Scholar
  36. 36.
    Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients with Raynaud’s phenomenon: a six year follow up with emphasis on the predictive value of antinu-clear antibodies as detected by immunoblotting. Ann Rheum Dis. 47: 634–641. 1988.PubMedCrossRefGoogle Scholar
  37. 37.
    Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G. The evolution of Raynaud’s phenomenon: a longterm prospective study. J Rheumatol. 22: 2226–2232. 1995.PubMedGoogle Scholar
  38. 38.
    Bynum WF. The Great Imitator: Syphilis in Historical Perspective. Medicine Int. 24: 12. 1996.Google Scholar
  39. 39.
    Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 27: 337–343. 1993.PubMedGoogle Scholar
  40. 40.
    Carrington PR, Sanusi ID, Zahradka S, Winder PR. Enalapril-associated erythema and vasculitis. Cutis. 51: 121–123. 1993.PubMedGoogle Scholar
  41. 41.
    Lanctot KL, Ghajar BM, Shear NH, Naranjo CA. Improving the diagnosis of hypersensitivity reactions associated with sulphonamides. J Clin Pharmacol. 34: 1228–1233. 1994.PubMedGoogle Scholar
  42. 42.
    Hannedouche T, Fillastre JP. Penicillin-induced hypersensitivity vasculitides. J Antimicrob Chemother. 20: 3–5. 1987.PubMedCrossRefGoogle Scholar
  43. 43.
    Stubbings J. Sheehan-Dare R, Walton S. Cutaneous vasculitis due to ciprofloxacin. Brit Med J. 305: 29. 1992.PubMedCrossRefGoogle Scholar
  44. 44.
    Ribard P, Kahn MF. Rheumatological side effects of quinolones. Clin Rheumatol. 5: 175–191. 1991.Google Scholar
  45. 45.
    Kelly JR, Andolsek K. Tetracycline toxicity presenting as generalised vasculitis. South Med J. 71: 961–963. 1978.PubMedCrossRefGoogle Scholar
  46. 46.
    Elkayam O, Yaron M, Caspi D. Minocycline induced arthritis assoicated with fever, livedo reticularis, and pANCA. Ann Rheum Dis. 55: 769–771. 1996.PubMedCrossRefGoogle Scholar
  47. 47.
    Bjornberg A, Gisslen H. Thiazides: A cause of necrotising vasculitis? Lancet. 2: 982–983. 1965.PubMedCrossRefGoogle Scholar
  48. 48.
    Cox NH, Hodkin P. Vasculitis due to metolazone. Postgrad Med J. 67: 860. 1991.PubMedCrossRefGoogle Scholar
  49. 49.
    Lin RY. Unusual autoimmune manifestations in furosemide-associated hypersensitivity angiitis. NY State J Med. 88: 439–440. 1988.Google Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  1. 1.Department of Internal MedicineSt. Luke’s HospitalGuardamangia, MaltaUSA

Personalised recommendations